Press Release Archive

(BUSINESS WIRE)--Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.1 months in patients treated with Sutent compared to 5.5 months in

(BUSINESS WIRE)--Pfizer Inc today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective Pfizer’s Registration Statement on Form S-4. The Form S-4 registers with the SEC Pfizer’s common stock to be issued in connection with the pending acquisition of Wyeth. In addition, the Form S-4 includes Wyeth’s Proxy Statement for its annual meeting of stockholders to be held on July 20, 2009, at which Wyeth

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, at the Goldman Sachs 30th Annual Global Healthcare Conference on Wednesday, June 10, 2009 at 9:40 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc today announced the successful completion of its offering of €5.85 billion and £1.50 billion of senior unsecured notes (totaling approximately $10.5 billion). The notes consist of: €1.85 billion of 3.625% notes due 2013 €2.00 billion of 4.75% notes due 2016 €2.00 billion of 5.75% notes due 2021 £1.50 billion of 6.50%

(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first line treatment of patients with advanced breast cancer. The independent Data Monitoring Committee (DMC) found that treatment with sunitinib in combination with paclitaxel would be unable to meet the primary endpoint of superior progression-

--(BUSINESS WIRE)--Pfizer announced today results from four studies highlighting clinical data with targeted treatment approaches in patients with non-small cell lung cancer (NSCLC). Data on the company’s oral c-Met and ALK inhibitor (PF-02341066), an investigational agent that selectively targets cancer-causing genes implicated in the progression of many cancers, will be presented at the 45th American Society of Clinical Oncology (ASCO

(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a conference call with investment analysts at 1:00 p.m. EDT on Friday, June 12, 2009. The purpose of the call is to review Phase 2 data for CP-690,550, Pfizer’s oral JAK-3 inhibitor, that will be presented during the Annual Congress of the European League Against Rheumatism (EULAR). To view and listen to the webcast,

(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and significantly expanding its portfolio of medicines in its Established Products Business Unit. Off-patent medicines, including branded generics, represent one of the fastest growth segments in the global pharmaceutical market. This is especially

(BUSINESS WIRE)--Pfizer Animal Health today announced that The European Commission has given Pfizer the go-ahead to market its innovative swine vaccine, Improvac®, across the European Union (EU). Improvac®, now approved in 52 countries around the world, provides a reliable reduction of boar taint in male pigs while improving the profitability and sustainability of pig production as well as the welfare of pigs. It represents an